Bionano Genomics terminates $200M ATM equity facility with Cowen, effective Feb 14, 2025

Bionano Genomics, Inc.

Terminated Sales Agreement with Cowen and Company effective Feb 14, 2025.
Agreement allowed sale of up to $200M in common stock via ATM program.
Company provided notice on Feb 4, 2025; no reason disclosed for termination.

item 1.02

Bionano Genomics, Inc. filing history →

Source: SEC EDGAR

accession 0001140361-25-003762

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.